Anti-D administration in pregnancy for preventing Rhesus alloimmunisation
Authors:
- Caroline A CrowtherCCCaroline A Crowther
- Philippa MiddletonPMPhilippa Middleton
- Rosemary D McBainRMRosemary D McBain
- 28 February 2013
- reference entry
- Published by Wiley
- No. 2,p. CD000020
Abstract
During pregnancy, a Rhesus negative (Rh-negative) woman may develop antibodies when her fetus is Rhesus positive (Rh-positive). These antibodies may harm Rh-positive babies. To assess the effects of antenatal anti-D immunoglobulin on the incidence of Rhesus D alloimmunisation when given to Rh-negative women without anti-D antibodies. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2012). Randomised trials in Rh-negative women without anti-D antibodies given anti-D after 28 weeks of pregnancy, compared with no treatment, placebo or a different regimen of anti-D. Two review authors independently assessed trial eligibility and risk of bias and extracted the data. Two trials with moderate to high risk of bias, involving over 4500 women, compared anti-D prophylaxis with no anti-D during pregnancy. When women received anti-D at 28 and 34 weeks' gestation, risks of immunisation were not significantly different than for women not given antenatal anti-D: risk ratio (RR) of immunisation during pregnancy was 0.42 (95% confidence interval (CI) 0.15 to 1.17); after the birth of a Rh-positive infant the RR was 0.42 (95% CI 0.15 to 1.17); and within 12 months after birth of a Rh-positive infant the RR was 0.39 (95% CI 0.10 to 1.62).However, women receiving anti-D during pregnancy were significantly less likely to register a positive Kleihauer test (which detects fetal cells in maternal blood) in pregnancy (RR 0.60, 95% CI 0.41 to 0.88) and at the birth of a Rh-positive infant (RR 0.60, 95% CI 0.46 to 0.79). No data were available for the risk of Rhesus D alloimmunisation in a subsequent pregnancy. No significant differences were seen for neonatal jaundice, and no adverse effects were reported in either trial. The risk of Rhesus D alloimmunisation during or immediately after a first pregnancy is about 1%. Administration of 100 µg (500 IU) anti-D to women in their first pregnancy can reduce this risk to about 0.2% without, to date, any adverse effects. Although unlikely to confer benefit in the current pregnancy, fewer women may have Rhesus D antibodies in any subsequent pregnancy, but the effects of this needs to be tested in studies of robust design.Keywords
This publication has 17 references indexed in Scilit:
- Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and QualityPLOS ONE, 2012
- General obstetrics: The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti‐D immunoglobulinBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functionsJournal of Clinical Investigation, 2005
- A review of the clinical effectiveness of routine antenatal anti‐D prophylaxis for rhesus‐negative women who are pregnantBJOG: An International Journal of Obstetrics & Gynaecology, 2004
- Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonistBlood, 2003
- Anti-D administration after childbirth for preventing Rhesus alloimmunisationCochrane Database of Systematic Reviews, 1997
- HEMOLYTIC DISEASE OF THE NEWBORNVox Sanguinis, 1996
- Multicentre trial of antepartum low‐dose anti‐D immunoglobulinTransfusion Medicine, 1995
- The Primary Rh0(D) Immune Response in Male VolunteersBritish Journal of Haematology, 1976
- ANÆMIA FROM BLEEDING OF THE FETUS INTO THE MOTHER'S CIRCULATIONThe Lancet, 1954